Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
MOUNJARO (Eli Lilly Australia Pty Ltd)
Product name
MOUNJARO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
tirzepatide
Registration type
NCE/NBE
Indication
Type 2 Diabetes Mellitus:
MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.